skip to Main Content

Retrospective Cohort Study of Risk of Hip Fractures Associated with High Dose, Long-term Proton Pump Inhibitor (HD-PPI) Use or H2 Receptor Antagonists (H2RA) and Cytochrome P450 Pharmacogenomics

This contract agreement with the FDA covers epidemiologic studies of drug safety questions identified by the FDA and led by KP researchers in Northern and Southern California. Examples of current studies include the cardiovascular safety of psychostimulant medications used for treating Attention Deficit Hyperactivity Disorder (ADHD), the effects of bisphosphonate medications on osteonecrosis of the jaw and and cardiac arrhythmias, and the safety of newer combination oral contraceptive agents.

Investigator: Go, Alan

Funder: U.S. Food and Drug Administration

Explore all studies and publications

Back To Top